scholarly journals Studies of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease

2009 ◽  
Vol 62 (9-10) ◽  
pp. 450-455 ◽  
Author(s):  
Vesna Radovic
Keyword(s):  
Myocardial Infarction ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Secondary Prevention ◽  
Ischemic Heart Disease ◽  
Beta Blockers ◽  
Convincing Evidence ◽  
Ischemic Heart ◽  
Necessary Condition ◽  
Professional Literature

Convincing evidence of the decline of mortality has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. The beta-blockers are also the most efficient antianginal medications for the decrease of ischemia in outpatients. They are highly efficient as a monotherapy for angina and are also a medication of choice for angina after the coronary. The objective of this work was an estimate of the use of beta-blockers in secondary prevention of the ischemic heart disease and eliminating doubts concerning their prescription. The method of the analysis sums up the results of a twenty-five- year study on of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease. The method of the work implies an examination of the professional literature and the data-bases, such as MEDLINE, PubMed and KOBSON. The first studies concerned non-selective beta-blockers, used orally. The following studies concerned cardioselective beta-blockers, metoprolol and atenolol. Several studies followed also the effect of beta-blockers and heparin, or beta-blockers and antagonists of calcium towards placebo, in patients with an unstable angina pectoris. Beta-blockers are an essential drug in secondary prevention of the myocardial infarction and in chronic heart failure. The necessary condition for the efficiency of beta-blockers is an early use. Beta-blockers should be given within 12 hours after the appearance of pain. The continuation of the therapy with beta-blockers after the acute phase is considered to be important in the decrease of the infarction zone expansion. Prophylactic use of beta-blockers after the coronary has an excellent effect, above all in patients with a minor, uncomplicated coronary. Though certain groups of beta-blockers have some special characteristics, when it comes to the treatment of angina pectoris, all beta-blockers are efficient. Generally, patients react well to them. Preference is given to cardioselective remedies, in patients with diabetes or lung disease. Exhaustive controlled clinical studies affirm beta-blockers as drugs that reduce mortality in secondary prevention of the ischemic heart disease.

scholarly journals Changes in the prevalence of metabolic syndrome and smoking habits during a 10-year period and relation between these risk factors and ischemic heart disease among men aged 45–64 years

Medicina ◽  
2008 ◽  
Vol 44 (5) ◽  
pp. 400 ◽  
Author(s):  
Dalia Lukšienė ◽  
Liucija Černiauskienė ◽  
Lilija Margevičienė ◽  
Abdonas Tamošiūnas
Keyword(s):  
Myocardial Infarction ◽  
Metabolic Syndrome ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Ischemic Heart Disease ◽  
Density Lipoprotein ◽  
Epidemiological Studies ◽  
Ischemic Heart ◽  
Smoking Habits ◽  
Previous Myocardial Infarction

The aim of this work was to compare the prevalence of metabolic syndrome and smoking habits smokingduring a 10-year period and to evaluate the association between metabolic syndrome and smoking habits, and ischemic heart disease among Kaunas men aged 45–64 years. Material and methods. In this study, we have used data from two epidemiological studies, which had been carried out according to the MONICA study protocol (359 men aged 45–64 years were enrolled in 1992–1993 and 408 men aged 45–64 years – in 2001–2002). The association between metabolic syndrome and smoking habits, and ischemic heart disease was established according to the data of 2001–2002 years. Ischemic heart disease was diagnosed based on the following criteria: previous myocardial infarction, angina pectoris, or ischemic changes in electrocardiogram. Metabolic syndrome was defined by Adult Treatment Panel III (ATP III) criteria. Results. The prevalence of ischemic heart disease did not change among men aged 45–64 years during a 10-year period. During this period, the decreased prevalence of metabolic syndrome was observed; decreased rate of hyperglycemia, decreased high-density lipoprotein cholesterol level, increased rate of hypertriglyceridemia, and increased waist circumference were noted. During this period, the proportion of regular male smokers increased significantly. After the evaluation of association between and metabolic syndrome and smoking habits, and ischemic heart disease (according to the data of 2001–2002 years), it was determined that the highest rate of ischemic heart disease was among regular smokers with metabolic syndrome (32.3%), and the lowest rate of ischemic heart disease was noted among men who had never smoked and were without metabolic syndrome (11.6%) (OR=3.63; P=0.013). The highest rate of previous myocardial infarction and/or angina pectoris was determined among regular smokers with metabolic syndrome (19.4%), and the lowest rate of ischemic heart disease was determined among men who had never smoked and were without metabolic syndrome (3.6%) (OR=6.43; P=0.008). Conclusion. Combination of metabolic syndrome and smoking is significantly associated with ischemic heart disease among men aged 45–64 years.

Correlations Between Acute Ischemic Stroke And Its Associated Cardiovascular Diseases

2014 ◽  
Vol 7 (2) ◽  
pp. 105-109
Author(s):  
Daniela Y. Arabadzhieva ◽  
Ara G. Kaprelyan ◽  
Zdravko D. Slavov ◽  
Zhaneta T. Georgieva ◽  
Aleksandra Zh. Tsukeva
Keyword(s):  
Myocardial Infarction ◽  
Heart Disease ◽  
Ischemic Stroke ◽  
Cardiovascular Diseases ◽  
Angina Pectoris ◽  
Ischemic Heart Disease ◽  
Acute Ischemic Stroke ◽  
Coronary Atherosclerosis ◽  
Ischemic Heart ◽  
Effort Angina

Summary The objective of this study was to analyze the association between some cardiovascular diseases and acute ischemic stroke. A total of 258 acute ischemic stroke patients (mean age 70.59±7.22 years) were examined. The presence of eight cardiovascular diseases and pathological conditions was analyzed: arterial hypertension, hypertensive heart, atrial fibrillation, myocardial infarction, ischemic heart disease, effort angina pectoris, coronary atherosclerosis, and heart failure. Data were statistically processed by variation and correlation analysis. Most male and female patients presented with four accompanying cardiovascular diseases (27 or 20.93% and 31 or 24.03% of the cases, respectively). There were two groups of four variables each - with a relatively strong and a moderate, as well as with a weak correlation (r<0.4), to the presence of acute ischemic stroke in the corresponding patients. Ischemic heart disease was strongly associated with effort angina pectoris (r=0.667) and to a lesser extent - with coronary atherosclerosis (r=0.470), whereas myocardial infarction was associated with coronary atherosclerosis (r=0.604) and ischemic heart disease (r=0.378), respectively. Arterial hypertension was moderately related to hypertensive heart (r=0.300). In conclusion, there were relatively close associations between acute ischemic stroke and these heart diseases. These patients should strictly and regularly be followed up by general practitioners.

scholarly journals Effect of Dementia on the Use of Drugs for Secondary Prevention of Ischemic Heart Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Nicole R. Fowler ◽  
Amber E. Barnato ◽  
Howard B. Degenholtz ◽  
Angela M. Curcio ◽  
James T. Becker ◽  
...  
Keyword(s):  
Heart Disease ◽  
Secondary Prevention ◽  
Ischemic Heart Disease ◽  
Cardiovascular Health ◽  
Beta Blockers ◽  
Ischemic Heart ◽  
Lipid Lowering ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
Converting Enzyme Inhibitors

Background. Dementia and cardiovascular disease (CVD) are frequently comorbid. The presence of dementia may have an effect on how CVD is treated.Objective. To examine the effect of dementia on the use of four medications recommended for secondary prevention of ischemic heart disease (IHD): angiotensin-converting enzyme inhibitors, beta-blockers, lipid-lowering medications, and antiplatelet medications.Design. Retrospective analysis of data from the Cardiovascular Health Study: Cognition Study.Setting and Subjects. 1,087 older adults in four US states who had or developed IHD between 1989 and 1998.Methods. Generalized estimating equations to explore the association between dementia and the use of guideline-recommended medications for the secondary prevention of IHD.Results. The length of follow-up for the cohort was 8.7 years and 265 (24%) had or developed dementia during the study. Use of medications for the secondary prevention of IHD for patients with and without dementia increased during the study period. In models, subjects with dementia were not less likely to use any one particular class of medication but were less likely to use two or more classes of medications as a group (OR, 0.60; 95% CI, 0.36–0.99).Conclusions. Subjects with dementia used fewer guideline-recommended medications for the secondary prevention of IHD than those without dementia.

Sign in / Sign up

Export Citation Format

Share Document